AMD

Valitor Announces Presentation on Novel Anti-VEGF Antibody Conjugate and Multivalent Polymer Technology Platform at Upcoming Ophthalmology Innovation Source (OIS) Summit

Retrieved on: 
Thursday, December 1, 2022

The presentation will review VLTR-557, an anti-VEGF therapy that is expected to provide effective therapy against wet age-related macular degeneration (AMD) with twice-yearly dosing based on preclinical findings.

Key Points: 
  • The presentation will review VLTR-557, an anti-VEGF therapy that is expected to provide effective therapy against wet age-related macular degeneration (AMD) with twice-yearly dosing based on preclinical findings.
  • Preclinical studies have demonstrated that VLTR-557 has an exceptional overall safety profile and does not leave residual depot materials within the eye.
  • VLTR-557 was created using the companys Multivalent Polymer (MVP) technology platform, which enables the development of novel macromolecular compounds through the use of biopolymers that can be engineered with multiple copies of bioactive molecules.
  • We are addressing this challenge with the development of our next generation anti-VEGF therapy, VLTR-557, and we look forward to keeping the community apprised of our progress as we begin IND-enabling studies.

Stellantis to Keynote at CES 2023

Retrieved on: 
Thursday, December 1, 2022

DETROIT, Dec. 1, 2022 /PRNewswire/ -- The Consumer Technology Association (CTA)® today announced Stellantis CEO Carlos Tavares as a keynote speaker at CES® 2023. The keynote address will feature the global unveiling of the Ram 1500 Revolution Battery Electric Vehicle Concept and the Peugeot Inception Concept. The presentation will chronicle Stellantis' vision for making mobility clean, safe and affordable for all.

Key Points: 
  • DETROIT, Dec. 1, 2022 /PRNewswire/ -- The Consumer Technology Association (CTA) today announced Stellantis CEO Carlos Tavares as a keynote speaker at CES 2023.
  • CES 2023 features Stellantis keynote, global unveiling of Ram 1500 Revolution BEV Concept & Peugeot Inception Concept.
  • He joins top executives from John Deere , AMD , BMW and Delta Air Lines as part of the CES keynote lineup.
  • CES 2023 will take place in person in Las Vegas, and digitally, Jan. 5-8, 2023.

AMD and Viettel Collaborate on 5G Mobile Network Expansion

Retrieved on: 
Thursday, December 1, 2022

SANTA CLARA, Calif., Dec. 01, 2022 (GLOBE NEWSWIRE) -- AMD (NASDAQ: AMD) and Viettel High Tech (Member of Viettel Group) today announced the successful completion of a 5G mobile network field trial deployment conducted by Viettel and powered by AMD Xilinx Zynq UltraScale+ MPSoC devices.

Key Points: 
  • SANTA CLARA, Calif., Dec. 01, 2022 (GLOBE NEWSWIRE) -- AMD (NASDAQ: AMD) and Viettel High Tech (Member of Viettel Group) today announced the successful completion of a 5G mobile network field trial deployment conducted by Viettel and powered by AMD Xilinx Zynq UltraScale+ MPSoC devices.
  • Designed to meet the growing capacity and performance requirements of mobile users globally, the Viettel 5G mobile network is expected to be completed by the end of 2022.
  • Viettel is committed to advancing mobile technology leadership by working closely with AMD to incorporate its adaptable SoC technology into our new generation of 5G networks, said Nguyen Vu Ha, general director of Viettel High Tech.
  • For more information about how AMD is enabling today and inspiring tomorrow, visit the AMD (NASDAQ: AMD) website , blog , LinkedIn and Twitter pages.

Ethernet Adapter Market Surpassed $1 B for the Third Consecutive Quarter, According to Dell'Oro Group

Retrieved on: 
Thursday, December 1, 2022

REDWOOD CITY, Calif., Dec. 1, 2022 /PRNewswire/ -- According to a recently published report by Dell'Oro Group, the trusted source for market information about the telecommunications, security, networks, and data center industries, the Ethernet controller and adapter market surpassed $1 billion for the third consecutive quarter. The shift of product mix to higher speed ports and rising prices drove recent revenue growth.

Key Points: 
  • REDWOOD CITY, Calif., Dec. 1, 2022 /PRNewswire/ -- According to a recently published report by Dell'Oro Group, the trusted source for market information about the telecommunications, security, networks, and data center industries, the Ethernet controller and adapter market surpassed $1 billion for the third consecutive quarter.
  • "The Ethernet controller and adapter market achieved strong double-digit growth year-over-year in 3Q 2022," said Baron Fung, Research Director at Dell'Oro Group.
  • Additional highlights from the 3Q 2022 Ethernet Adapter and Smart NIC report include:
    The Ethernet controller and adapter market is on track for 43 percent revenue growth in 2023.
  • Ethernet controller and adapter port shipments are expected to decline in 2023 as the market undergoes digestion.

Cognition Therapeutics Presents Scientific Rationale, Clinical Biomarker and Preclinical Data supporting a Phase 2 Clinical Trial with CT1812 in Geographic Atrophy Secondary to Dry AMD

Retrieved on: 
Thursday, December 1, 2022

Complement inhibition has shown potential in clinical trials but must be given via intravitreal injection to each affected eye.

Key Points: 
  • Complement inhibition has shown potential in clinical trials but must be given via intravitreal injection to each affected eye.
  • CT1812 is an experimental oral sigma-2 (-2) receptor modulator currently in Phase 2 clinical trials for both Alzheimer's disease and dementia with Lewy bodies (DLB).
  • The proteomic analyses from our clinical studies in neurodegenerative disease were instrumental in identifying dry AMD as an indication of interest, explained Mary Hamby, Ph.D. , VP of biology at Cognition Therapeutics.
  • We are currently investigating our lead candidate CT1812 in clinical programs in Alzheimers disease, dementia with Lewy bodies (DLB) and dry age-related macular degeneration (dry AMD).

Outlook Therapeutics® to Participate in the Cantor Fitzgerald Medical & Aesthetic Dermatology, Ophthalmology & Medtech Conference

Retrieved on: 
Thursday, December 1, 2022

In addition to the panel presentation, management will be available to participate in in-person one-on-one meetings with qualified members of the investor community who are registered to attend the conference.

Key Points: 
  • In addition to the panel presentation, management will be available to participate in in-person one-on-one meetings with qualified members of the investor community who are registered to attend the conference.
  • The panel discussion is open to those who are registered to attend the event.
  • The FDA accepted Outlook Therapeutics BLA submission for ONS-5010 to treat wet AMD with a PDUFA goal date of August 29, 2023.
  • The submission is supported by Outlook Therapeutics wet AMD clinical program, which consists of three clinical trials: NORSE ONE, NORSE TWO, and NORSE THREE.

SparingVision’s lead asset SPVN06 clears IND application in the US for the treatment of retinitis pigmentosa

Retrieved on: 
Thursday, December 1, 2022

SparingVision has also submitted a clinical trial authorisation (CTA) application to the French regulator (ANSM), which is currently under review.

Key Points: 
  • SparingVision has also submitted a clinical trial authorisation (CTA) application to the French regulator (ANSM), which is currently under review.
  • First safety data are anticipated in 2023 and the primary endpoint is expected to be reached in 2025.
  • With over 80 genes involved in RP, each with numerous causative mutations, we need to go beyond the gene-by-gene treatment approach.
  • SPVN06 has the potential to become the universal therapeutic solution that patients need, and we are excited for the next phase of development.

CES 2023 on Track for Record Post-Pandemic Growth

Retrieved on: 
Wednesday, November 30, 2022

ARLINGTON, Va., Nov. 30, 2022 /PRNewswire/ -- As anticipation builds for CES® 2023, the Consumer Technology Association (CTA)® today held a virtual press conference highlighting record post-pandemic sales and continued momentum that, if held today, make CES 2023 50% bigger than CES 2022.

Key Points: 
  • ARLINGTON, Va., Nov. 30, 2022 /PRNewswire/ -- As anticipation builds for CES 2023, the Consumer Technology Association (CTA) today held a virtual press conference highlighting record post-pandemic sales and continued momentum that, if held today, make CES 2023 50% bigger than CES 2022.
  • CES 2023 on track for record post-pandemic growth.
  • Visit CES.tech for all CES 2023 updates, registration details and the media page for all press resources.
  • CES 2023 will take place in person in Las Vegas, and digitally, Jan. 5-8, 2023.

AMD to Present at Arete’s Tech Conference

Retrieved on: 
Wednesday, November 30, 2022

SANTA CLARA, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Today, AMD (NASDAQ: AMD) announced that Mark Papermaster, chief technology officer and executive vice president, Technology and Engineering, will present at the virtual Arete Tech Conference (ATC) on Tuesday, Dec. 6 at 10:10 AM ET/7:10 AM PT.

Key Points: 
  • SANTA CLARA, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Today, AMD (NASDAQ: AMD) announced that Mark Papermaster, chief technology officer and executive vice president, Technology and Engineering, will present at the virtual Arete Tech Conference (ATC) on Tuesday, Dec. 6 at 10:10 AM ET/7:10 AM PT.
  • Areplay of the webcast can be accessed after the conclusion of the live event and will be available for one year after the conference.
  • AMD employees are focused on building leadership high-performance and adaptive products that push the boundaries of what is possible.
  • For more information about how AMD is enabling today and inspiring tomorrow, visit the AMD (NASDAQ: AMD) website , blog , LinkedIn , Facebook and Twitter pages.

Canadians are Skipping Regular Eye Exams Despite Available Vision Benefits

Retrieved on: 
Wednesday, November 30, 2022

The results of a recent Specsavers Canadian Eye Exam Survey, conducted by Leger, included insights into the behaviour of Canadians and their habits when it comes to their eye health.

Key Points: 
  • The results of a recent Specsavers Canadian Eye Exam Survey, conducted by Leger, included insights into the behaviour of Canadians and their habits when it comes to their eye health.
  • One-in-four Canadians who do not wear corrective lenses have not had an eye exam in at least 10 years, including 10% of Canadians who have never had an eye exam.
  • With regular eye exams including Optical Coherence Tomography (OCT) patients can receive comprehensive information about their eye health," says Naomi Barber, Director of Optometry, Specsavers Canada.
  • Fifty-seven percent of Canadians who do not wear glasses say that vision worsening over time would cause them to increase the frequency of seeking eye exams.